厄贝沙坦对急性脑梗死患者血浆溶血磷脂酸和血清超敏C反应蛋白的影响

Impact of Irbesartan on Plasma Lysophosphatidic Acid and Serum High Sensitivity C-reactive Pro- tein in Patients with Acute Cerebral Infarction

【目的】观察厄贝沙坦对急性脑梗死患者血浆溶血磷脂酸（LPA）和血清超敏C反应蛋白（hs-CRP）含量的影响。【方法】将78例急性脑梗死患者依据治疗方法分为厄贝沙坦治疗组（A组，39例）和常规治疗组（B组，39例），另选取40名健康体检者作为对照组。A组给予厄贝沙坦150mg联合阿司匹林100mg，每日1次；B组给予阿司匹林100mg，每日1次；两组其余治疗方法相同，连续治疗两周。在治疗前、后测定LPA和hs-CRP含量，并评定其临床疗效。【结果】A，B两组脑梗死患者血浆LPA和血清hs-CRP含量较对照组均显著升高（均P〈0．01），LPA和hs-cRP含量与爱登堡斯堪的那维亚卒中量表（NDs）呈正相关；A，B两组治疗后血浆LPA和血清hs-cRP含量和NDS与治疗前相比较均明显降低，其差异有显著性意义（P〈0．01）；A组治疗前后血浆LPA和血清hs-CRP含量的差值与B组比较差异有显著性（P〈0．05）。【结论】厄贝沙坦能明显降低急性脑梗死患者的血浆LPA和血清hs-CRP，并有助于脑梗死患者的神经功能恢复。

[Objective]To observe the impact of irbesartan（Irb） on plasma lysophosphatidic acid（LPA） and serum high sensitivity C-reactive proteln（hs-CRP） in patients with acute cerebral infarction. [Methods] According to treatment methods, 78 patients with acute cerebral infarction were divided into Irb group（group A, n=39） and conventional therapy group（group B, n=39）. Other 40 subjects receiving physical examination were selected as control group. Group A was given Irb 150mg combined with aspirin 100mg once a day. Group B was given aspirin 100mg once a day. The rest therapy methods of two groups were the same. All patients were treated continuously for 2 weeks. The levels of LPA and hs-CRP before and after treatment were measured. Clinical efficacy was evaluated. [Results]Compared with control group, plasma LPA and serum hs-CRP in patients with acute cerebral infarction of group A and group B significantly increased（both P〈 0.01）. The levels of LPA and hs-CRP were positively related with NDS. There were significant differences in plasma LPA, serum hs-CRP and NDS in group A and group B between before and after treatment（ P 〈0.01）. There were sig- nificant differences in deviation value of plasma LPA and serum hs-CRP before and after treatment between group A and group B（ P 〈0. 05）. [Conclusion] Irb can obviously reduce plasma LPA and serum hs-CRP in patients with acute cere- bral infarction, and contribute to the recovery of neurological function in patients with cerebral infarction.